The role of α-synuclein in Parkinson's disease: insights from animal models

The abnormal accumulations of fibrillar α-synuclein in Lewy bodies and the mutations in the gene for α-synuclein in familial forms of Parkinson's disease have led to the belief that this protein has a central role in a group of neurodegenerative diseases known as the synucleinopathies. Our understanding of the biology of α-synuclein has increased significantly since its discovery in 1997, and recently developed animal models of the synucleinopathies have contributed to this understanding. The information gleaned from animal models has the potential to provide a framework for continuing the development of rational therapeutic strategies.

[1]  C. C. Johnson,et al.  The risk of Parkinson's disease with exposure to pesticides, farming, well water, and rural living , 1998, Neurology.

[2]  C A Ross,et al.  Synphilin‐1 is present in Lewy bodies in Parkinson's disease , 2000, Annals of neurology.

[3]  Georg Auburger,et al.  The ubiquitin pathway in Parkinson's disease , 1998, Nature.

[4]  M. Mouradian.  Recent advances in the genetics and pathogenesis of Parkinson disease , 2002, Neurology.

[5]  Nigel J. Cairns,et al.  Filamentous α-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies , 1998, Neuroscience Letters.

[6]  J. C. Greene,et al.  Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[7]  M. Won,et al.  The ceruloplasmin and hydrogen peroxide system induces α-synuclein aggregation in vitro , 2002 .

[8]  Ronald L Klein,et al.  Dopaminergic cell loss induced by human A30P alpha-synuclein gene transfer to the rat substantia nigra. , 2002, Human gene therapy.

[9]  P. Auluck,et al.  Pharmacological prevention of Parkinson disease in Drosophila , 2002, Nature Medicine.

[10]  E. Tolosa,et al.  Mitochondrial respiratory chain activity in skeletal muscle from patients with Parkinson's disease. , 1993, Neurology.

[11]  Nancy A. Jenkins,et al.  Human α-synuclein-harboring familial Parkinson's disease-linked Ala-53 → Thr mutation causes neurodegenerative disease with α-synuclein aggregation in transgenic mice , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[12]  C. Marsden,et al.  Indices of oxidative stress in Parkinson's disease, Alzheimer's disease and dementia with Lewy bodies. , 1997, Journal of neural transmission. Supplementum.

[13]  Richard Paylor,et al.  Synaptic Vesicle Depletion Correlates with Attenuated Synaptic Responses to Prolonged Repetitive Stimulation in Mice Lacking α-Synuclein , 2002, The Journal of Neuroscience.

[14]  A. Iwamatsu,et al.  Oxidized forms of peroxiredoxins and DJ-1 on two-dimensional gels increased in response to sublethal levels of paraquat , 2001, Free radical research.

[15]  D. Allsop,et al.  Formation of hydrogen peroxide and hydroxyl radicals from Aβ and α-synuclein as a possible mechanism of cell death in Alzheimer’s disease and Parkinson’s disease. , 2002 .

[16]  Peter T Lansbury,et al.  Beta-synuclein inhibits formation of alpha-synuclein protofibrils: a possible therapeutic strategy against Parkinson's disease. , 2003, Biochemistry.

[17]  A H Schapira,et al.  Free radical scavengers protect dopaminergic cell lines from apoptosis induced by complex I inhibitors. , 1997, Brain research.

[18]  J. Langston,et al.  Electron microscopy of Lewy bodies in the amygdala-parahippocampal region. Comparison with inclusion bodies in the MPTP-treated squirrel monkey. , 1996, Advances in neurology.

[19]  E. Junn,et al.  Human α-Synuclein over-expression increases intracellular reactive oxygen species levels and susceptibility to dopamine , 2002, Neuroscience Letters.

[20]  Patrizia Rizzu,et al.  Mutations in the DJ-1 Gene Associated with Autosomal Recessive Early-Onset Parkinsonism , 2002, Science.

[21]  Nobutaka Hattori,et al.  Ubiquitination of a New Form of α-Synuclein by Parkin from Human Brain: Implications for Parkinson's Disease , 2001, Science.

[22]  David A. Lewis,et al.  Implications for Parkinson ' s Disease , 2022 .

[23]  T. Iwatsubo,et al.  α‐Synuclein Inclusions in Amygdala in the Brains of Patients with the Parkinsonism‐Dementia Complex of Guam , 2000, Journal of neuropathology and experimental neurology.

[24]  S. Totterdell,et al.  Lysosomal malfunction accompanies alpha-synuclein aggregation in a progressive mouse model of Parkinson’s disease , 2002, Brain Research.

[25]  J B Schulz,et al.  Sensitivity to MPTP is not increased in Parkinson's disease‐associated mutant α‐synuclein transgenic mice , 2001, Journal of neurochemistry.

[26]  J. Trojanowski,et al.  Neuronal α-Synucleinopathy with Severe Movement Disorder in Mice Expressing A53T Human α-Synuclein , 2002, Neuron.

[27]  Bruce A. Yankner,et al.  Dopamine-dependent neurotoxicity of α-synuclein: A mechanism for selective neurodegeneration in Parkinson disease , 2002, Nature Medicine.

[28]  P. Lansbury,et al.  Inhibition of fibrillization and accumulation of prefibrillar oligomers in mixtures of human and mouse alpha-synuclein. , 2000, Biochemistry.

[29]  P. Lansbury,et al.  Accelerated Oligomerization by Parkinson's Disease Linked α‐Synuclein Mutants , 2000 .

[30]  J. Couzin.  Dopamine May Sustain Toxic Protein , 2001, Science.

[31]  Peter T. Lansbury,et al.  Kinetic Stabilization of the α-Synuclein Protofibril by a Dopamine-α-Synuclein Adduct , 2001, Science.

[32]  R. Burke,et al.  α‐Synuclein expression in substantia nigra and cortex in Parkinson's disease , 1999 .

[33]  Makoto Hashimoto,et al.  β-Synuclein Inhibits α-Synuclein Aggregation A Possible Role as an Anti-Parkinsonian Factor , 2001, Neuron.

[34]  W. Bender,et al.  A Drosophila model of Parkinson's disease , 2000, Nature.

[35]  V. Lee,et al.  Parkin and the Molecular Pathways of Parkinson's Disease , 2001, Neuron.

[36]  H. Paulson,et al.  Suppression of polyglutamine-mediated neurodegeneration in Drosophila by the molecular chaperone HSP70 , 1999, Nature Genetics.

[37]  J Q Trojanowski,et al.  Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. , 1998, The American journal of pathology.

[38]  B. Sommer,et al.  Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[39]  K. Jellinger,et al.  Clinical and neuropathological correlates of Lewy body disease , 2003, Acta Neuropathologica.

[40]  Philippe Hantraye,et al.  MPTP induces alpha‐synuclein aggregation in the substantia nigra of baboons , 2000, Neuroreport.

[41]  M. Citron,et al.  alpha-synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson's disease. , 1999, The Journal of biological chemistry.

[42]  T. Iwatsubo,et al.  Phosphorylation of α-synuclein characteristic of synucleinopathy lesions is recapitulated in α-synuclein transgenic Drosophila , 2003, Neuroscience Letters.

[43]  A. Lees,et al.  Ageing and Parkinson's disease: substantia nigra regional selectivity. , 1991, Brain : a journal of neurology.

[44]  M. L. Schmidt,et al.  α-Synuclein in Lewy bodies , 1997, Nature.

[45]  Peter T. Lansbury,et al.  Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson disease , 1998, Nature Medicine.

[46]  C. Haass,et al.  Physiology and Pathophysiology of α‐Synuclein: Cell Culture and Transgenic Animal Models Based on a Parkinson's Disease‐associated Protein , 2000, Annals of the New York Academy of Sciences.

[47]  C. Stichel,et al.  The mouse MPTP model: gene expression changes in dopaminergic neurons , 2003, The European journal of neuroscience.

[48]  R. Pendleton,et al.  Effects of pharmacological agents upon a transgenic model of Parkinson's disease in Drosophila melanogaster. , 2002, The Journal of pharmacology and experimental therapeutics.

[49]  Todd B. Sherer,et al.  Chronic systemic pesticide exposure reproduces features of Parkinson's disease , 2000, Nature Neuroscience.

[50]  Gary Fiskum,et al.  Generation of reactive oxygen species by the mitochondrial electron transport chain , 2002, Journal of neurochemistry.

[51]  Stephen M. Mount,et al.  The genome sequence of Drosophila melanogaster. , 2000, Science.

[52]  T. Südhof,et al.  Role of α-synuclein in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice , 2003, Neuroscience.

[53]  G. Petsko,et al.  The 1.1-Å resolution crystal structure of DJ-1, the protein mutated in autosomal recessive early onset Parkinson's disease , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[54]  Ted M. Dawson,et al.  Neuroprotective and neurorestorative strategies for Parkinson's disease , 2002, Nature Neuroscience.

[55]  M. Zigmond,et al.  A Role for α-Synuclein in the Regulation of Dopamine Biosynthesis , 2002, The Journal of Neuroscience.

[56]  K. Hensley,et al.  Interaction of α‐Phenyl‐N‐tert‐Butyl Nitrone and Alternative Electron Acceptors with Complex I Indicates a Substrate Reduction Site Upstream from the Rotenone Binding Site , 1998, Journal of neurochemistry.

[57]  David F. Clayton,et al.  Characterization of a novel protein regulated during the critical period for song learning in the zebra finch , 1995, Neuron.

[58]  Jung-Hoon Kang,et al.  Enhanced oligomerization of the alpha-synuclein mutant by the Cu,Zn-superoxide dismutase and hydrogen peroxide system. , 2003, Molecules and cells.

[59]  P. Lansbury,et al.  The UCH-L1 Gene Encodes Two Opposing Enzymatic Activities that Affect α-Synuclein Degradation and Parkinson's Disease Susceptibility , 2002, Cell.

[60]  S. Minoshima,et al.  Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism , 1998, Nature.

[61]  T. Oltersdorf,et al.  Neuron-specific transgene expression of Bcl-XL but not Bcl-2 genes reduced lesion size after permanent middle cerebral artery occlusion in mice , 1999, Neuroscience Letters.

[62]  A. Blackburn,et al.  Parkinson's disease, pesticides, and glutathione transferase polymorphisms , 1998, The Lancet.

[63]  A. Björklund,et al.  Parkinson-Like Neurodegeneration Induced by Targeted Overexpression of α-Synuclein in the Nigrostriatal System , 2002, The Journal of Neuroscience.

[64]  David W. Miller,et al.  L166P Mutant DJ-1, Causative for Recessive Parkinson's Disease, Is Degraded through the Ubiquitin-Proteasome System* , 2003, Journal of Biological Chemistry.

[65]  J. Trojanowski,et al.  Selective Insolubility of α-Synuclein in Human Lewy Body Diseases Is Recapitulated in a Transgenic Mouse Model , 2001 .

[66]  J. Vickers,et al.  Localization of α-, β-, and γ-synuclein during neuronal development and alterations associated with the neuronal response to axonal trauma , 2003, Experimental Neurology.

[67]  Howard J. Federoff,et al.  Behavioral and Neurochemical Effects of Wild-Type and Mutated Human α-Synuclein in Transgenic Mice , 2002, Experimental Neurology.

[68]  M. Vila,et al.  Engineered modeling and the secrets of Parkinson's disease , 2001, Trends in Neurosciences.

[69]  E. Masliah,et al.  α-Synuclein is phosphorylated in synucleinopathy lesions , 2002, Nature Cell Biology.

[70]  Y Nakamura,et al.  [Problems of long-term levodopa therapy in Parkinson's disease]. , 1997, Nihon rinsho. Japanese journal of clinical medicine.

[71]  L. Tremblay,et al.  Experimental Models of Parkinson’s Disease , 2002, Annales pharmaceutiques francaises.

[72]  N. Bonini.  Chaperoning brain degeneration , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[73]  Isao Nishimura,et al.  Parkin Suppresses Dopaminergic Neuron-Selective Neurotoxicity Induced by Pael-R in Drosophila , 2003, Neuron.

[74]  A. Björklund,et al.  Nigrostriatal α-synucleinopathy induced by viral vector-mediated overexpression of human α-synuclein: A new primate model of Parkinson's disease , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[75]  Vladimir N. Uversky,et al.  Amino acid determinants of α‐synuclein aggregation: putting together pieces of the puzzle , 2002 .

[76]  B. Hyman,et al.  Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies. , 2002, The American journal of pathology.

[77]  L. Mucke,et al.  Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. , 2000, Science.

[78]  P. Lansbury,et al.  Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[79]  P. Aebischer,et al.  α-Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[80]  H. Budka,et al.  14‐3‐3 Proteins in Lewy Bodies in Parkinson Disease and Diffuse Lewy Body Disease Brains , 2002, Journal of neuropathology and experimental neurology.

[81]  A. Mitsumoto,et al.  DJ-1 is an indicator for endogenous reactive oxygen species elicited by endotoxin , 2001, Free radical research.

[82]  P. Lansbury,et al.  Vesicle permeabilization by protofibrillar alpha-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism. , 2002, Biochemistry.

[83]  J. Culvenor,et al.  α-synuclein fibrils constitute the central core of oligodendroglial inclusion filaments in multiple system atrophy , 2003, Experimental Neurology.

[84]  Robert L. Nussbaum,et al.  Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .

[85]  Pico Caroni,et al.  Neuropathology in Mice Expressing Human α-Synuclein , 2000, The Journal of Neuroscience.

[86]  John Hardy,et al.  The A53T α-Synuclein Mutation Increases Iron-Dependent Aggregation and Toxicity , 2000, The Journal of Neuroscience.

[87]  Heidi Phillips,et al.  Mice Lacking α-Synuclein Display Functional Deficits in the Nigrostriatal Dopamine System , 2000, Neuron.

[88]  J. Langston,et al.  Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. , 1983, Science.

[89]  M. Farrer,et al.  Lack of Nigral Pathology in Transgenic Mice Expressing Human α-Synuclein Driven by the Tyrosine Hydroxylase Promoter , 2001, Neurobiology of Disease.

[90]  Robert Burke,et al.  Resistance of α-synuclein null mice to the parkinsonian neurotoxin MPTP , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[91]  I. Weissman,et al.  Implications for Pathogenesis and Therapy , 1996 .

[92]  C. Marín,et al.  Mitochondria1 respiratory chain activity in skeletal muscle from patients with Parkinson's disease , 1993, Neurology.

[93]  D. Neill,et al.  Aggregates from mutant and wild‐type α‐synuclein proteins and NAC peptide induce apoptotic cell death in human neuroblastoma cells by formation of β‐sheet and amyloid‐like filaments , 1998, FEBS letters.

[94]  O. Blin,et al.  Mitochondrial respiratory failure in skeletal muscle from patients with Parkinson's disease and multiple system atrophy , 1994, Journal of the Neurological Sciences.